Pharmaceuticals

Covis Group S.à r.l. Announces Commencement of Tender Offer for All Outstanding Shares of AMAG Pharmaceuticals, Inc.

LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") announced the commencement of a cash tender offer to purchase all of the outstanding shares of common stock of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) ("AMAG"). The tender offer is being made pursuant ...

2020-10-15 19:30 12595

Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference

HONG KONG, Oct. 15, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from multiple studies in Asian population that evaluated the safety and efficacy of switching to once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir...

2020-10-15 14:10 7556

Thrive Bioscience Launches the CellAssist to Provide Imaging, Analytics, and Documentation for Reproducible Cell Culture

WAKEFIELD, Massachusetts, Oct. 15, 2020 /PRNewswire/ -- Thrive Bioscience introduces the CellAssist® which enables cell culture researchers to image, analyze, and document all cells, plates, reagents, and workflow details in a centralized database. The CellAssist was developed by Thrive Biosci...

2020-10-15 11:00 3824

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

SHANGHAI, Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, and WuXi Biologics ("WuXi Bio") (2269.HK) a...

2020-10-15 08:59 2766

CUREMARK Honored by Goldman Sachs for Entrepreneurship

Dr. Joan M. Fallon, CEO and Founder Among 100 Most Intriguing Entrepreneurs at 2020 Builders + Innovators Summit  RYE BROOK, New York, Oct. 15, 2020 /PRNewswire/ -- Goldman Sachs (NYSE: GS) is recognizing Curemark's Founder and CEO Dr.Joan M. Fallon as one of the 100 Most Intriguing Entrepreneur...

2020-10-15 03:22 10008

SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan

PANGYO, Gyeonggi Province, Korea, Oct. 13, 2020 /PRNewswire/ -- SK Biopharmaceuticals and Ono Pharmaceutical announced that they have entered into an exclusive licensing agreement for Ono to develop and commercialize cenobamate inJapan. Cenobamate is a treatment for partial-onset seizures (POS) ...

2020-10-13 21:00 3760

Envirotainer Unleashes Free Shipment reports

STOCKHOLM, Oct. 13, 2020 /PRNewswire/ -- Envirotainer, the global market leader and the by far largest provider of temperature-controlled air freight solutions for pharmaceuticals, today announced that they open up unlimited and free access to shipment data for all their customers. The shipment d...

2020-10-13 14:38 1950

AGC Biologics Appoints Luca Alberici as the New General Manager/Site Head of the Milan, Italy Site

SEATTLE, Oct. 12, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a new appointment to initiate integration efforts resulting from theJuly 31, 2020 acquisition of MolMed, a biotechnology company focus...

2020-10-12 20:00 4269

Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapies in oncology and hematology, announced today, the official opening of the Ant...

2020-10-12 20:00 4996

The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study

LUND, Sweden, Oct. 12, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002 ("BRaVac"), is expected to be further delayed due to the prevailing Covid-19 pandemic. The recruitm...

2020-10-12 15:03 2293

Enrolment of First Two Patients in PRISTINE Study with SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, Oct. 12, 2020 /PRNewswire/ -- MedAlliance has announced enrolment of the first two patients in the PRISTINE registry with SELUTION SLR™ 018 DEB for the treatment of patients with Below The Knee disease (Chronic Limb Threatening Ischemia). This is the first DEB accepted by the F...

2020-10-12 13:56 4532

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...

2020-10-12 08:30 8672

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...

2020-10-12 08:30 7801

CStone Announces Completion of $200 million Share Sale to Pfizer

SUZHOU, China, Oct. 12, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today the completion of the Share Subscription Agreement through which an affiliate of Pfizer Inc. ("Pfizer", NYSE: PFE) subscribed for newly issued CStone shares at approximatelyUS$200 million (e...

2020-10-12 08:05 6159

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...

2020-10-09 19:14 11738

TropIQ Health Sciences Digitalises Its Discovery Platform with CDD Vault

CDD Vault will enable TropIQ Health Sciences to share research results with partners in real time NIJMEGEN, Netherlands and SAN FRANCISCO, Oct. 9, 2020 /PRNewswire/ -- TropIQ Health Sciences, a  biotechnology social enterprise with a dual purpose to provide enabling technologies and expertise in...

2020-10-09 12:00 2631

CBC-incubated Everest Medicines Successfully Lists on HKEX

SHANGHAI, Oct. 9, 2020 /PRNewswire/ -- CBC Group ("CBC"), a healthcare-dedicated investment platform, today celebrates the initial public offering (IPO) of Everest Medicines ("Everest") (1952.HK), a portfolio company incubated by CBC, on the Stock Exchange ofHong Kong. Everest Medicines is a l...

2020-10-09 09:31 11810

Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

SUZHOU, China and ROCKVILLE, MD., Oct. 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...

2020-10-09 08:21 3050

Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA

TAIPEI, Oct. 8, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") announced today that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the ...

2020-10-09 06:39 2034

Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate

Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on beh...

2020-10-08 23:22 10000
1 ... 276277278279280281282 ... 313

Week's Top Stories